Kornimate/medical-research-clean huggingface dataset:
radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery

Conditions: Low-grade Glioma

Summary: it has been reported that radiation therapy followed by pcv chemotherapy (procarbazine, lomustine and vincristine) could improve progression-free survival (pfs) and overall survival (os) in patients with high-risk who grade 2 gliomas after surgery. however, procarbazine is not available in china. in clinical practice, chinese doctors often use radiotherapy combined with temozolomide to treat these patients, though large-scale prospective studies are lacking. this trial aims to confirm whether rt combined with temozolomide can improve pfs and os in patients with high-risk low-grade gliomas.


Eligibility criteria:
inclusion criteria: 1. newly diagnosed supratentorial who grade ii gliomas; 2. aged 18 to 39 years without total resection, or aged 40 to 70 years with any extent of resection or biopsy; 3. karnofsky performance score (kps) ≥ 60; 4. no more than moderate neurologic symptoms and signs; 5. the interval between surgery and randomization is less than 12 weeks; 6. have signed the consent form. - exclusion criteria: 1. who grade i gliomas or high-grade gliomas according to who's grading system; 2. have received prior radiation therapy to the head and neck region; 3. have received prior chemotherapy; 4. synchronous multiple primary malignant tumor excluding carcinoma of the cervix in situ or nonmelanomatous skin cancer; 5. prior malignancy's disease-free survival less than 5 years; 6. have active infection; 7. patients are pregnant or breast-feeding. -

Keywords: low-grade glioma high-risk radiotherapy temozolomide
fibrinolysis compared to thoracoscopy for pleural infection

Conditions: Pleural Infection; Pleural Diseases

Summary: the purpose of this prospective randomized clinical trial is to compare two currently accepted standard-of-care treatment strategies: medical thoracoscopy as compared to instillation of intrapleural tissue plasminogen activator (tpa) and human recombinant deoxyribonuclease (dnase) for the management of empyema or complex parapneumonic effusion (cppe) in adults.

background: pleural infection (empyema or complex parapneumonic effusion (cppe)) represents one of the most common clinical diagnoses encountered in clinical practice in the united states (us) it is associated with substantial morbidity and mortality despite advances in medical diagnostic and therapeutic strategies. objective: compare two standard of care treatments: tpa/dnase vs early medical thoracoscopy methods: we will conduct a prospective randomized clinical trial. we plan to enroll a total of 80 patients and randomize them to either medical thoracoscopy group or fibrinolytic therapy group. follow-up will be daily until hospital discharge and at 6 and 12 weeks in the outpatient setting primary outcome: duration of hospital stay after intervention secondary outcome: failure rate of assigned treatment and adverse events potential outcome and benefit: determine best strategy for treating patients with pleural infection

Eligibility criteria:
inclusion criteria: * subjects \>18 years old with: * evidence of empyema or complex parapneumonic effusion exclusion criteria: * age \<18 years * pregnancy * inability to give informed written consent * previous thoracic surgery or thrombolytic therapy for pleural infection * medical thoracoscopy cannot be performed within 48 hours * hemodynamic instability or severe hypoxemia * non corrected coagulopathy * homogeneously echogenic effusion on pleural ultrasonography
a study of xeloda (capecitabine) in patients with advanced and/or metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this study will assess the efficacy and safety of intermittent oral xeloda administration in combination with irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. the anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * locally advanced and/or metastatic colorectal cancer; * \>=1 target lesion. exclusion criteria: * previous treatment with xeloda or irinotecan; * previous systemic therapy for metastatic disease; * progressive disease during previous adjuvant therapy or within 6 months of completion.
breathing exercises for asthma

Conditions: Asthma

Summary: despite the advances in pharmacological therapy for asthma, there has been an increasing worldwide interest in alternative therapies for asthma. treatments and therapies such as yoga, acupuncture, homeopathy, hypnosis and buteyko and other breathing techniques have been used as complementary therapies however little evidence exists behind such practices. data from systemic reviews and randomized control trials provide evidence of benefit although additional confirmation is still needed. among the most common techniques are the buteyko breathing exercises that aim to reduce minute ventilation by instruct asthmatics patients to breathe shallowly and slowly through the nose. the second common technique is the pranayama, or yoga breathing exercises which emphasizes deep respirations and exhalation prolongation. our goal is to assess the effectiveness of breathing exercises as a complementary therapy for asthma.


Eligibility criteria:
inclusion criteria: * adults age 18-65 of either sex, with a physician-diagnosed history of persistent asthma. * access to internet exclusion criteria: * subjects with history of copd or any other lung disease, pregnant or lactating women, no access to internet and patients who cannot communicate in english.

Keywords: adults age 18-65 physician-diagnosed persistent asthma
goal-directed vs preemptive tranexamic acid administration in non-cardiac surgery

Conditions: Arthritis Knee; Spine Fusion; Prostate Cancer; Arthritis of Hip; Hepatic Cancer

Summary: the present study is a multi-center randomized prospective non-inferiority trial. the study's primary objective is to compare the coagulation profile upon using two different txa administration strategies: empirical txa administration vs. viscoelastic test-based goal-directed txa administration in high-risk non-cardiac surgery. the secondary objectives include comparing the amount of bleeding, incidents of hyper-fibrinolysis, thromboembolic complications, and postoperative seizures. researchers assumed that goal-directed tranexamic acid (txa) administration using viscoelastic field tests would not be inferior to the empirical txa administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. it also would be beneficial in lowering txa-induced thromboembolic complications and seizures.

the present study is a multi-center randomized prospective placebo-controlled non-inferiority trial. this study's primary objective is to compare the coagulation profile upon using two different txa administration strategies: empirical txa administration vs. viscoelastic test-based goal-directed txa administration in non-cardiac surgery. the secondary objectives include determining the inter-group differences in hyper-fibrinolysis, during postoperative 2bleeding, thromboembolic complications, and postoperative seizures. researchers hypothesized that goal-directed txa administration using viscoelastic field tests would not be inferior to the empirical txa administration strategy in reducing postoperative bleeding and hyper-fibrinolysis. researchers also expect that goal-directed txa administration would be beneficial in lowering txa-induced thromboembolic complications and seizure risks.

Eligibility criteria:
inclusion criteria patients undergoing following surgery * spinal fusion surgery with more than 2 levels * total hip arthroplasty * total knee arthroplasty * open prostatectomy * hepatectomy exclusion criteria: * pregnancy * refusal of allogenic blood transfusion * taking thrombin * history of thromboembolic and familial hypercoagulability disease * recent history of myocardial infarction or ischemic cerebral infarction (within 90 days) * hypersensitive to txa * histroy of convulsion or epilepsy * taking hemodialysis * history of heparin-induced thrombocytopenia

Keywords: bleeding viscoelastic test tranexamic acid transfusion thromboembolism fibrinolysis seizure
prospective study of children and adolescents with craniopharyngioma

Conditions: Craniopharyngioma; Obesity

Summary: the present investigation is a prospective, multicenter study evaluating craniopharyngioma patients' prognoses following the various currently-practiced therapeutic strategies.primary goals of the study are to establish quality standards and compare the various therapy strategies with respect to their effectiveness and impact on the quality of life of treated patients. a stratified randomization of two treatment arms will be conducted with respect to timing of postoperative irradiation for the subgroup of patients ≥5 years of age whose tumors are incompletely resected. the researchers will investigate whether an immediate, postoperative irradiation is superior to progression-contingent irradiation based on alterations to quality of life (pedqol) from the time randomization is initiated (3rd month post op) to 3 years after randomization. progression-free survival and overall survival will be examined as closely-related subgoals.postoperative data will be evaluated via a surveillance study for all complete resection patients as well as for those patients under 5 years of age regardless of their resection grade.


Eligibility criteria:
inclusion criteria: 1. diagnosed with craniopharyngioma for the first time 2. age at diagnosis 18 years or less of age 3. agreement from patient's parents or legal guardian as well as the patient criteria for inclusion in randomization study 1. histological diagnosis of craniopharyngioma 2. age at diagnosis 18 years or less of age 3. age at primary surgery over 5 years of age 4. incomplete primary resection 5. reference radiological confirmation of an incomplete resection 6. agreement from patient's parents or legal guardian as well as the patient exclusion criteria: age at diagnosis over 18 years of age no qol measurement for randomization (3 months after surgery).

Keywords: quality of life endocrinology oncology hypothalamus irradiation neurosurgery pediatric brain tumors randomized trial
pilot study for investigating the effect of the bruder eye hydrating compress on contact lens discomfort in contact lens wearers

Conditions: Contact Lens Discomfort; Dry Eye Disease; Meibomian Gland Dysfunction

Summary: the purpose of this prospective study is to evaluate the benefits of using the bruder moist heat compress in contact lens wearers who report reduced comfortable wear time. this will be done by assessing for improvement in ocular oil gland function and comfortable contact lens wearing time after one month of daily warm compress application. the efficacy of the bruder moist heat compress applied once will be compared to twice daily application as well as compared to warm compress application using a wash cloth.


Eligibility criteria:
inclusion criteria: * 18 years or older * provide informed consent and authorization to disclose protected health information * have habitual contact lens corrected visual acuity in each eye of at least 20/30 * willing to comply with protocol * wear soft daily contact lenses for total wear time of at least 4 hours a day and at least 4 days a week on average over at least a 30 day period before enrollment exclusion criteria: * have any uncontrolled systemic disease that in the investigator's opinion could be expected to interfere with the study, for example, conditions associated with dry eye disease * pregnant by self-report * active ocular conditions: infection, allergic conjunctivitis, severe eyelid inflammation including anterior blepharitis

Keywords: contact lens discomfort dry eye disease meibomian gland dysfunction bruder mask
anti-secretory drug in treatment of acute watery diarrhea

Conditions: Acute Watery Diarrhea

Summary: in conclusion, racecadotril is an anti-secretory drug that exerts its antidiarrheal effect by inhibiting intestinal enkephalinase. it is effective in reducing the volume and frequency of stool output. racecadotril is well tolerated and safe by providing symptomatic relief and reducing the severity of diarrhea as an adjuvant therapy during the acute attack of gastroenteritis. it is recommended that the new generations of already discovered drugs for control of secretory diarrhea should be studied to discover the ones with fewer side effects to other systems in the body.

background: previous studies have shown that racecadotril is a safe and effective drug in treating children with acute diarrhea. study aim: to evaluate the effect of racecadotril as an adjunct to oral rehydration solution in the treatment of acute watery diarrhea among children under 5 years of age. subjects and methods: this rct trial included 50 children with acute watery diarrhea for 5 days or less with a frequency of three or more diarrheic stools in the past 24 hours before admission to the hospital, with no/mild to moderate dehydration.

Eligibility criteria:
inclusion criteria: * age group for six months - 5 years. * no or mild to moderate dehydration. * alert patient (to tolerate oral intake since the drug is only available in oral form). exclusion criteria: * patients with severe dehydration (inability to drink because of drowsiness). * patients with any serious concomitant illness that needs antibiotic treatment. * if severe adverse events occur at any time. * chronic diarrhea.
trial to investigate immune responses elicited by a liquid formulation of influenza virus vaccine (caiv-t) in healthy children

Conditions: Influenza

Summary: to perform a variety of assays on blood, nasal washes, and cells obtained from healthy children for the purposes of further investigation of immune responses generated by influenza virus vaccine, trivalent, types a and b, live, cold-adapted (liquid caiv-t; wyeth lederle vaccines, marietta, pa). • to assess nasal swab specimens to detect vaccine virus shedding.

this was a phase ii, prospective, randomized, partially-blinded, placebo-controlled, outpatient study conducted at multiple sites throughout the us in healthy children aged 6 months to less than 36 months. parents/guardians of subjects were asked to read and sign the informed consent before any study-related procedures were performed. subjects at each study site were sequentially assigned to 1 of 2 separate blood sample groups referred to as "cellular immunity" or "antibody secreting cell". subjects within each blood sample group were then randomized 1:1:1:1 to receive a single intranasal dose of caiv-t 10\^7 ffu per dose, caiv-t 10\^5 ffu per dose, placebo or a commercially-available injectable trivalent influenza vaccine (tiv).

Eligibility criteria:
inclusion criteria: * children at least 6 months of age and less than 36 months of age at the time of enrollment, and in good health as determined by medical history, physical examination and clinical judgement; * whose parent/legal guardian has provided written informed consent after the nature of the study has been explained; * who, along with their parent or guardian, will be available for the one month duration of the trial (from enrollment to study completion); exclusion criteria: * whose parents or guardians are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period; * with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease; * with down's syndrome or other known cytogenetic disorders; * with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids, or cytotoxic agents (see section 4.2.2); * have an immunosuppressed or an immunocompromised individual living in the same household; * with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine, placebo or tiv; * who, at anytime prior to study enrollment, receives any influenza vaccine (commercial or investigational); * with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results. note: a pregnant household member is not considered a contraindication to enrollment.
role of antifungal prophylaxis in elderly patients with acute myeloid leukemia during consolidation therapy

Conditions: Invasive Aspergillosis

Summary: in previous retrospective study (seifem 2016 study) the investigators evaluated the incidence of proven/probable invasive aspergillosis (ia) and the role of mold active primary antifungal prophylaxis (pap) in a "real life" setting of acute myeloid leukemia (aml )patients receiving intensive consolidation therapy. all cases of proven/probable ia, observed during consolidation chemotherapy in adult and pediatric aml patients between 2011 and 2015, were retrospectively collected in a multicenter study involving 38 italian hematologic centers. the investigators observed 56 (2.2%) cases of ia \[43 probable (1.7%) and 13 proven (0.5%)\]. the overall mortality rate and the mortality rate attributable to ia (amr) on day 120 were 16% and 9%, respectively. in multivariate analysis, parameters that influenced the outcome were age ≥60 years and treatment with high doses of cytarabine (hdac). the investigators also observed that centers involved in this survey had different antifungal policies during the aml consolidation phase. the results from this study show that in a large real-world setting the mold active pap, with itraconazole or posaconazole, decreases the rate of ia after consolidation course. in seifem 2016 study the investigators demonstrated that the incidence of ia during the aml consolidation is low. however, the mortality is not negligible, mainly in older patients. further, a sub-analysis in the subset of patients older than 60 years demonstrated that patients who didn't receive mold active prophylaxis had higher incidence of ia than patients who received mold active prophylaxis (15% vs 6%). therefore, as prophylaxis seems to prevent ia in consolidation, further studies should be performed especially in elderly patients treated with hdac to confirm our data and to identify the subset of patients who require pap.

evaluate the protective role of mold active pap in patients older than 60 years underwent to chemotherapy of consolidation with intermediate or high doses of cytarabine

Eligibility criteria:
inclusion criteria: * signed written informed consent according to ich/eu/gcp and national/local laws * patients aged older than 60 years underwent to consolidation course with intermediate/high doses of cytarabine exclusion criteria: • diagnosis of ia during induction course and previous antifungal treatment
uric acid levels and endothelial functions

Conditions: Coronary Artery Disease

Summary: uric acid is a risk factor for coronary artery disease (ced) in postmenopausal women but the association with inflammation and coronary microvascular endothelial dysfunction is not well-defined. the aim of this study was to determine the relationship of serum uric acid, inflammatory markers and ced.


Eligibility criteria:
inclusion criteria: * referred to mayo clinic for cardiac catheterization * postmenopausal exclusion criteria: * history of percutaneous coronary intervention * coronary artery bypass graft surgery * unstable angina pectoris * valvular heart disease * peripheral vascular disease * known congestive heart failure

Keywords: uric acid microvascular dysfunction inflammation
efficacy and safety of cipro xr versus cipro ir in patients with complicated urinary tract infections

Conditions: Urinary Tract Infection

Summary: to assess and compare the efficacy and safety of ciprofloxacin extended-release (cipro xr) tablet 1000 mg po once-daily (od) versus ciprofloxacin immediate-release (cipro ir) tablet 500 mg po twice-daily (bid) for 7-14 days in patients with complicated and/or nosocomial urinary tract infections (cuti).


Eligibility criteria:
inclusion criteria: the primary diagnosis in this clinical trial was cuti in men or non-pregnant women over 18 years of age. other main inclusion criteria: * one or more clinical symptoms and signs of a lower uti: fever (\> 38°c, orally), chills, frequency of micturition, dysuria, urge sensation. * one or more of the following underlying conditions suggestive of cuti: * indwelling urinary catheter. * 100 ml of residual urine after voiding. * neurogenic bladder. * obstructive uropathy due to lithiasis, tumor or fibrosis. * acute urinary retention in men. exclusion criteria: diagnosis of pyelonephritis supported by clinical signs/symptoms of fever (\>38°c orally), chills and flank pain (all 3 signs/symptoms must be present). * have a history of allergy to quinolones * are unable to take oral medication * have an intractable infection requiring \> 14 days of therapy * have a requirement for concomitant administration of sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminum or calcium * have prostatitis or epididymitis * have had a renal transplant * have ileal loop or vesica- urethral reflux * have significant liver or kidney impairment * have a history of tendinopathy associated with fluoroquinolones * are pregnant, nursing * have a history of convulsions or cns disorders
influencing factors on dry eye syndrome and ocular surface disease

Conditions: Dry Eye Syndrome; Ocular Surface Disease

Summary: dry eye syndrome and ocular surface disease are very important ophthalmologic diseases. it is known that various inducers are involved. however, it is still necessary to study how influencing factors are related to dry eye syndrome and ocular surface disease and how treatment for dry eye syndrome and ocular surface disease is helpful.


Eligibility criteria:
inclusion criteria: * patients with ocular discomfort related to ded who visit the hallym university kangnam sacred heart hospital between june 2016 and june 2017. exclusion criteria: * subjects who are elderly (≥80 years old) or have an autoimmune disease (e.g., sjögren's syndrome and systemic lupus erythematosus) are excluded.